Genentech's sefaxersen reduces proteinuria 43.1% versus placebo in phase III IgA nephropathy trial
Genentech said interim phase III results showed sefaxersen reduced proteinuria by 43.1% versus placebo in adults with IgA nephropathy; treatment effects were consistent across prespecified subgroups, with no new safety signals.
1. Interim trial results
Genentech announced interim phase III results showing that investigational sefaxersen significantly reduced urinary protein versus placebo in adults with IgA nephropathy. Results were presented at the American Society of Nephrology Kidney Week 2026 on Oct. 23.
2. Trial continues
Treatment effects were consistent across prespecified patient subgroups, with no new safety signals. The IMAgINATION trial will continue evaluating kidney function over two years. Sefaxersen is designed as a once-monthly injection for self-administration at home.
